Panacea Biotec Limited has announced a major international achievement, securing a Letter of Award from UNICEF for the long-term supply of bivalent oral polio vaccine (bOPV). The contract will run from April 1, 2026, to March 31, 2030, with deliveries scheduled during Q2 CY2026 and CY2027.
Under this agreement, Panacea Biotec will supply bOPV in 10-vial and 20-vial presentations, with the total contract valued at approximately US$ 35.65 million (around ₹315 crore). The vaccines will be provided as per UNICEF’s requirements and global procurement programs.
UNICEF has outlined that the award details, including supplier name, vaccine type, duration, contract value, and pricing per product presentation, will be published publicly on its official platform.
This international order further strengthens Panacea Biotec’s position as a trusted global vaccine supplier. The company confirmed that neither its promoters nor group companies hold any interest in UNICEF, and the contract does not fall under related-party transactions.
The deal marks another significant milestone for Panacea Biotec in supporting global immunization programs and combating polio worldwide.
